Compare STHO & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STHO | JSPR |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.7M | 68.4M |
| IPO Year | N/A | N/A |
| Metric | STHO | JSPR |
|---|---|---|
| Price | $7.62 | $1.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $25.60 |
| AVG Volume (30 Days) | 47.9K | ★ 3.8M |
| Earning Date | 11-07-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $117,547,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.06 | $1.39 |
| 52 Week High | $10.63 | $23.11 |
| Indicator | STHO | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 46.29 |
| Support Level | $7.56 | $1.60 |
| Resistance Level | $7.77 | $1.93 |
| Average True Range (ATR) | 0.20 | 0.20 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 25.42 | 36.90 |
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties and land and development properties.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.